Sanofi Completes Vigil Neuroscience Acquisition
Ticker: SNYNF · Form: 6-K · Filed: Aug 7, 2025 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Aug 7, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, healthcare, biotech
Related Tickers: VIGL
TL;DR
Sanofi just bought Vigil Neuroscience, adding to their rare disease drug efforts.
AI Summary
On August 6, 2025, Sanofi announced the completion of its acquisition of Vigil Neuroscience, Inc. The filing incorporates a press release detailing this significant development in Sanofi's business strategy.
Why It Matters
This acquisition allows Sanofi to expand its pipeline in rare neurological diseases, potentially leading to new treatments for patients.
Risk Assessment
Risk Level: low — The filing is a routine report on a completed acquisition and does not introduce new financial risks.
Key Players & Entities
- Sanofi (company) — Acquiring company
- Vigil Neuroscience, Inc. (company) — Acquired company
- August 6, 2025 (date) — Date of acquisition completion announcement
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report that Sanofi has completed the acquisition of Vigil Neuroscience, Inc., as detailed in a press release dated August 6, 2025.
When was the acquisition of Vigil Neuroscience, Inc. completed?
The acquisition was completed in August 2025, with the press release announcing it dated August 6, 2025.
What is Sanofi's SIC code?
Sanofi's Standard Industrial Classification (SIC) code is 2834, for Pharmaceutical Preparations.
Where is Sanofi's principal executive office located?
Sanofi's principal executive office is located at 46, avenue de la Grande Armée, 75017 Paris, France.
Does Sanofi file annual reports under Form 20-F or Form 40-F?
Sanofi indicates that it files annual reports under Form 20-F.
Filing Stats: 177 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2025-08-07 12:39:31
Filing Documents
- d745635d6k.htm (6-K) — 8KB
- d745635dex991.htm (EX-99.1) — 15KB
- g745635g0807203652328.jpg (GRAPHIC) — 3KB
- g745635g0807204246137.jpg (GRAPHIC) — 1KB
- 0001193125-25-175232.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: August 7, 2025 SANOFI By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3